The effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension
10.3760/cma.j.issn.0253-3758.2013.04.009
- VernacularTitle:苯磺酸左旋氨氯地平治疗轻中度原发性高血压的疗效和安全性
- Author:
Tan JIA
1
;
Li-Jun ZHANG
;
Yi-Qiang ZHAN
;
Jin-Ming YU
;
Da-Yi HU
Author Information
1. 复旦大学公共卫生学院 公共卫生安全教育部重点实验室
- Keywords:
Hypertension;
Amlodipine;
Randomized controlled trials
- From:
Chinese Journal of Cardiology
2013;41(4):301-303
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension.Method A total of 1051 mild to moderate essential hypertensives were recruited from 22 centers and randomized into three groups and were given low-dose L-amlodipine besylate (2.5 mg/d),high-dose L-amlodipine besylate (5.0 mg/d),and amlodipine maleate (5.0 mg/d) on the principle of open-label and parallel control.The study drugs were administered for 8 weeks.Results After 8 weeks treatments,the response rate of the three groups were 72.4％,85.6％,and 76.2％,respectively.The rate difference between high-dose L-amlodipine besylate group and the other two groups were statistically significant (P ＜ 0.01),while the rate difference between low-dose L-amlodipine besylate group and amlodipine maleate group was similar (P =0.28).The event rates of the three groups were similar (4.3％,4.6％,and 5.1％,respectively,P =0.84).Conclusion High-dose L-amlodipine besylate is superior to the other 2 groups on blood pressure control.The efficacy profiles of amlodipine maleate and low-dose L-amlodipine besylate are equivalent.Safety profiles of these three groups are comparable.
